Lupin launches antidepressant tablets in US
New Delhi: Drug firm Lupin has launched its antidepressant Bupropion Hydrochloride extended release tablets used for treatment of major depressive disorder in the US market.
The company has launched its generic tablets in the strengths of 150 mg and 300 mg after having received approval from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.
The company's tablets are generic versions of Valeant Pharmaceuticals North America LLC's Wellbutrin XL Tablets in the same strengths, it added.
The product is indicated for treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder in adults.
"Wellbutrin XL tablets had sales of USD 758 million as per IMS MAT May 2017", Lupin said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd